Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure

Stojanovic K. S., Delmas Y., Torres P. U., Peltier J., Pelle G., Jeru I., ...More

NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.27, no.5, pp.1898-1901, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 5
  • Publication Date: 2012
  • Doi Number: 10.1093/ndt/gfr528
  • Journal Name: NEPHROLOGY DIALYSIS TRANSPLANTATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1898-1901
  • Keywords: AA amyloidosis, colchicine, familial Mediterranean fever, interleukine-1 inhibitors, renal failure, COLCHICINE, TOXICITY
  • Dokuz Eylül University Affiliated: No

Abstract

Background. Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder, for which systemic AA amyloidosis is the major complication revealed most of the time by renal abnormalities. Current treatment is daily colchicine that prevents both recurrent inflammatory attacks and amyloidosis deposition in most patients. However, some patients still develop amyloidosis and renal failure. Functional studies suggest that interleukin (IL)-1 is implicated in the inflammatory reaction in FMF and therefore, IL-1 inhibitors could be a new approach to treat FMF. The aim of this series study was to evaluate anakinra in patients with FMF complicated with amyloidosis and renal failure.